Coeliac disease – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Mon, 22 Jun 2026 04:02:10 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Coeliac disease – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Gaxilose (LacTEST 0.45 g) to evaluate intestinal barrier integrity and permeability in patients with celiac disease https://clinicaltrials.eu/trial/study-of-gaxilose-to-assess-intestinal-barrier-integrity-and-permeability-in-patients-with-celiac-disease/ Fri, 19 Jun 2026 04:03:42 +0000 https://clinicaltrials.eu/trial/study-of-gaxilose-to-assess-intestinal-barrier-integrity-and-permeability-in-patients-with-celiac-disease/ People with celiac disease have an immune reaction to gluten that damages the lining of the small intestine, reducing the ability to absorb nutrients. The study evaluates a diagnostic powder called LacTEST 0.45 g, which is taken orally and measures the amount of the enzyme that breaks down lactose, known as intestinal lactase activity. Researchers also want to see if the test can reflect the condition of the intestinal barrier, the protective layer that normally prevents unwanted substances from passing into the body.

The purpose of the study is to determine whether the test can serve as a simple marker of intestinal health in people following a gluten‑free diet. Participants will take the powder and provide urine samples to measure how much a sugar called xylose is excreted, and they will have blood draws to check levels of antitransglutaminase antibodies, which indicate ongoing immune activity. Additional assessments include a microscopic grading system called the Marsh-Oberhuber classification, a stool test called the L/M test, and measurements of proteins such as LBP, sCD14, and zonulin that relate to gut permeability. Over the course of about a year, participants will attend periodic visits for these tests and complete questionnaires about symptoms and quality of life, allowing researchers to track changes as the intestinal lining heals.

]]> Study of TEV-53408 Safety and Effectiveness in Adults with Celiac Disease During Gluten Exposure https://clinicaltrials.eu/trial/study-on-the-effects-and-safety-of-tev-53408-for-adults-with-celiac-disease-during-gluten-exposure/ Wed, 29 Apr 2026 15:04:24 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-and-safety-of-tev-53408-for-adults-with-celiac-disease-during-gluten-exposure/ This clinical trial focuses on studying a new medication called TEV-53408 for people with celiac disease. Celiac disease is a condition where eating gluten (a protein found in wheat, rye, and barley) causes damage to the small intestine. The purpose of this study is to evaluate how well TEV-53408 works to protect the intestine from damage when people with celiac disease are exposed to gluten.

The study will test a single dose of TEV-53408 given as a subcutaneous injection (an injection under the skin) compared to a placebo. During the study, participants will need to eat food containing gluten while researchers monitor how their intestines respond to the treatment. The study will last 28 weeks to assess both the effectiveness and safety of the medication.

Participants will undergo medical examinations including an endoscopy (a procedure where a small camera is used to look inside the intestine) to check how the intestinal tissue responds to the treatment. The study will track any changes in the intestinal lining and monitor for any side effects that may occur during the treatment period.

]]> Study on the Effects of Amlitelimab for Adults with Non-Responsive Celiac Disease https://clinicaltrials.eu/trial/study-on-the-effects-of-amlitelimab-for-adults-with-non-responsive-celiac-disease/ Wed, 29 Apr 2026 14:59:58 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-amlitelimab-for-adults-with-non-responsive-celiac-disease/ This clinical trial is focused on studying celiac disease, a condition where the body’s immune system reacts to gluten, a protein found in wheat, barley, and rye. The study is investigating a treatment called amlitelimab, which is given as a solution for injection under the skin. The purpose of the study is to evaluate how effective and safe amlitelimab is in helping adults with non-responsive celiac disease, which means their symptoms do not improve even when they follow a gluten-free diet.

Participants in the study will receive either amlitelimab or a placebo, which looks like the treatment but does not contain the active medicine. The study will last for several months, during which participants will continue their gluten-free diet. Some participants may also be exposed to gluten to see how the treatment works under different conditions. Throughout the study, participants will have regular check-ups and tests to monitor their health and any changes in their symptoms.

The main goal is to see if amlitelimab can improve the condition of the intestinal lining, which is often damaged in people with celiac disease. The study will also track any side effects and measure the levels of amlitelimab in the blood. This research aims to provide new insights into managing celiac disease for those who do not respond well to a gluten-free diet alone.

]]> Study on the Effects of KAN-101 and Sodium Chloride in Adults with Celiac Disease https://clinicaltrials.eu/trial/study-on-the-effects-of-kan-101-and-sodium-chloride-in-adults-with-celiac-disease/ Wed, 29 Apr 2026 14:30:34 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-kan-101-and-sodium-chloride-in-adults-with-celiac-disease/ This clinical trial is focused on studying celiac disease, a condition where the immune system reacts to gluten, a protein found in wheat, barley, and rye, causing damage to the small intestine. The study will evaluate a new treatment called KAN-101, which is being tested to see if it can help reduce the changes in the small intestine caused by gluten in people with celiac disease. Participants in the study will receive either KAN-101 or a placebo, which is a substance with no active medication, to compare the effects.

The purpose of the study is to assess how well KAN-101 can protect the small intestine from damage when gluten is introduced. This will be done by looking at changes in the structure of the small intestine through a procedure called esophagogastroduodenoscopy, which involves using a small camera to take a look inside the digestive tract. The study will also monitor the safety and tolerability of KAN-101 by checking for any side effects and measuring the levels of the drug in the blood.

Participants will be involved in the study for a period of time, during which they will undergo a gluten challenge, meaning they will consume gluten to see how their body responds with and without the treatment. The study will last for a few weeks, and participants will have regular check-ups to monitor their health and the effects of the treatment. The goal is to find out if KAN-101 can be a safe and effective treatment option for people with celiac disease.

]]> Study on ZED1227 for Improving Symptoms in Celiac Disease Patients on a Gluten-Free Diet https://clinicaltrials.eu/trial/study-on-zed1227-for-improving-symptoms-in-celiac-disease-patients-on-a-gluten-free-diet/ Wed, 29 Apr 2026 14:30:10 +0000 https://clinicaltrials.eu/trial/study-on-zed1227-for-improving-symptoms-in-celiac-disease-patients-on-a-gluten-free-diet/ This clinical trial is focused on studying Celiac Disease, a condition where the immune system reacts to gluten, a protein found in wheat, barley, and rye, causing damage to the small intestine. The study aims to evaluate the effectiveness and safety of a new treatment called ZED1227, which is taken in the form of a hard capsule. Participants in the trial will either receive the ZED1227 capsules or a placebo, which looks like the medication but does not contain the active ingredient.

The purpose of the study is to see if ZED1227 can help improve symptoms of Celiac Disease in individuals who continue to experience symptoms despite following a gluten-free diet. The trial will involve participants taking the capsules for a period of 15 weeks. During this time, participants will continue their usual gluten-free diet and will be asked to report their symptoms using a diary specifically designed for Celiac Disease symptoms.

Throughout the study, participants will have regular check-ups to monitor their health and any changes in their symptoms. The trial will assess the improvement in symptoms such as diarrhea, abdominal pain, bloating, and nausea, as well as any changes in the condition of the small intestine. The study is designed to provide valuable information on whether ZED1227 can be a beneficial treatment for those with Celiac Disease who are not fully relieved by a gluten-free diet alone.

]]>